8-K filed Aug 3, 2026 at 07:04 ET
Krystal Biotech reported Q2 2026 VYJUVEK revenue of $119.2M (+24% YoY), slightly below the $121.0M consensus, with GAAP diluted EPS of $1.79 vs. the Street consensus of $1.70, representing a beat. The company maintained its FY 2026 non-GAAP R&D and SG&A expense guidance of $175-195M. The quarter showed strong commercial execution with 730+ reimbursement approvals and 640+ prescribers, while the pipeline advanced with multiple registrational readouts expected in 2H 2026, including top-line data for KB803 in 4Q 2026. The slight revenue miss relative to consensus tempers the otherwise positive operational update, resulting in a neutral-to-modestly-bullish read.